问题 › 我们需要一份给银行的商业计划书 › 健康科技与数字健康
银行审阅的不是雄心，而是看在风险收入依赖参与率和归因结果时，下行情景是否仍能覆盖债务。 数字健康公司面临特定困境——结果风险签署速度快于公司验证自身承担能力所需时间，12个月测量窗口对11个月销售周期。在风险定价前，风险收入份额会因无法归因的原因持续变动，债务覆盖率的讨论始终停留在意见层面。
银行审阅的不是雄心，而是看在风险收入依赖参与率和归因结果时，下行情景是否仍能覆盖债务。 数字健康公司面临特定困境——结果风险签署速度快于公司验证自身承担能力所需时间，12个月测量窗口对11个月销售周期。在风险定价前，风险收入份额会因无法归因的原因持续变动，债务覆盖率的讨论始终停留在意见层面。
为银行写的计划书通常在同一处失败：只有单一乐观情景，没有可见算式将风险收入份额与参与率或客户流失率挂钩。审阅者要判断在适度不利情况下能否收回资金，仅有好情景的计划书无法提供测试PMPM或毛利率变动的依据。
能通过审查的是：带明确参与率和归因结果假设的基础情景、真正糟糕而非简单下调的下行情景，以及从经营表现到两种情景下债务服务的清晰路径。上行情景最不重要。
第二个失败点是不一致——收入线无法与注册会员或风险份额对账，或毛利率不随参与率变动。银行审阅者每天都在找这类问题。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 你需要在别人设定的截止日期前拿到文件
✓ 预测存在于外部无人针对客户流失或PMPM变动做过压力测试的表格里
✓ 没有风险收入份额的下行情景，或下行情景只是基础情景减去参与率的固定调整
通常会让情况更糟的做法。 把计划书写成有说服力，而不是可核查参与率如何影响债务服务——这是最快失去每天核查文件的读者的方式。
It is for you if you run or finance a digital health company and you need the document by a deadline set by someone else. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Business Plan Studio, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
短到能读完，完整到能测试。财务数据和背后假设决定结果，多余叙事只会增加风险而非信心。
非好情景下的现金流能否覆盖债务，以及数字内部是否自洽。其他几乎都是这两点的背景。
匹配融资期限，第一年按月。超出贷款期限的细节显示不熟悉而非严谨。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית